Neurocrine Biosciences made a $2.9 billion statement about where it sees its growth coming from when it closed the Soleno Therapeutics deal in May 2026, and now it is organizing its leadership to match that ambition. Promoting Samir Siddhanti to Chief Business Officer is not a routine succession move. It is the company signaling that the architect of that acquisition, and of the broader pipeline expansion strategy, will sit at the executive table as Neurocrine tries to compound on a commercial base that already spans tardive dyskinesia, Huntington’s disease, congenital adrenal hyperplasia, and Prader-Willi syndrome.
What makes the appointment structurally interesting is Siddhanti’s dual identity inside the company. He has been the business development operator who structured transactions, but he has also served as Program Team Leader for direclidine, Neurocrine’s oral muscarinic M4 agonist in Phase 3 for schizophrenia with Phase 2 data expected in bipolar mania. That drug lands in one of the most competitive therapeutic spaces in psychiatry right now, with muscarinic-class competitors already approved. Siddhanti knows the science, knows the competitive dynamics, and knows how to structure partnerships around assets under pressure. That combination is exactly what Neurocrine needs to maximize direclidine’s value, whether through independent commercialization, co-promotion, or licensing.
His background at Goldman Sachs on the biotech equity research team matters here too, and not as a resume footnote. It means he spent years building models on what the market rewards in drug development pipelines, before switching to the side that builds them. That outside-in lens, applied over nearly a decade of internal dealmaking at Neurocrine, is a real asset when a company is deciding how aggressively to pursue external opportunities versus deploying capital on internal programs. The Soleno acquisition at $53 per share in cash was a high-conviction, high-cost bet on Prader-Willi syndrome hyperphagia. The next major allocation decision will define whether Neurocrine’s pipeline depth translates into durable revenue diversification or just a crowded asset list.
The concrete marker to track is direclidine’s Phase 3 schizophrenia topline readout. Siddhanti now owns the strategic response to that data at the executive level. How Neurocrine chooses to position, partner, or protect that program in a muscarinic-class market that already has an approved competitor will be the first real test of what this leadership restructuring actually produces.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
